Sartorius Stedim Biotech launches ambr 15 bioreactor system with Nova BioProfile FLEX2 integration
Sartorius Stedim Biotech’s ambr 15 bioreactor system now can be combined with Nova’s BioProfile FLEX2 automated cell culture analyser.
QbD studies in upstream processing more rapidly performed.
Sartorius Stedim Biotech (SSB) has announced that the ambr 15 automated micro bioreactor system combined with a Nova Biomedical (Nova) BioProfile FLEX2 automated cell culture analyser is on show for the first time at the Cell Line Development & Engineering Conference in San Diego, California. This newly integrated system, which is a first from SSB and Nova’s successful collaboration, enables rapid at-line sample collection and analysis of massive quantities of key cell culture data.
SSB and Nova have collaborated to seamlessly integrate the software interface that controls the ambr 15 workstation for automated parallel processing of 24 or 48 single-use bioreactors (10–15 mL working volume) with the cell culture analysis capabilities of the innovative BioProfile FLEX2. The combined system provides a unique tool to simultaneously run, sample and analyse a massive number of cell culture conditions during cell line and media development by Design of Experiments (DoE).
Combining the ambr 15 and the BioProfile FLEX2 enables fully integrated automatic sample transfer, analysis and automated feedback control in each single-use ambr 15 bioreactor. This allows collection of enormous quantities of cell culture data, including total and viable cell density, viability, cell diameter, pH, PCO2, PO2, glucose, lactate, glutamine, glutamate, ammonium, Na+, K+, Ca++ and osmolality, which can be sampled and measured with a complete cycle time of just 6–7 minutes. The ambr 15 software simultaneously acquires the BioProfile FLEX2 data set and processes it, for example, by performing complex in-run calculations of how much feed volume to automatically add during a run. This saves time by significantly increasing the amount of consistent clone selection, media development and culture parameter data that a scientist can generate per run.
“We have combined two highly innovative technologies. Our successful partnership with Nova has delivered complete at-line analytics capabilities for our ambr 15 platform. Utilizing these integrated systems will support scientists to more easily run full QbD studies, without causing a sampling bottleneck or needing additional staff resources. The new system will optimize their process productivity, as well as the quality of their biologics,” stated Dr Barney Zoro, ambr Product Manager at SSB.
“There is a significant demand for fully automated cell culture analysis of small-volume culture systems like the Sartorius ambr micro bioreactor system,” said Matthew McRae, Biotechnology Sales Product Line Manager at Nova. “We’re excited to have worked with SSB on this integration program because our BioProfile FLEX2 with maintenance-free sensors provides rapid analysis of key cell culture tests using just 265 microliters of sample. As a result, this analyzer is a highly complementary addition to the ambr 15 while maintaining the flexibility and modularity of the first-generation BioProfile FLEX analyser.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...